Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially ...
Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival ...
Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential ...
Mutations in the triggering receptor expressed on myeloid cells 2 (TREM2) have been identified as risk factors for late-onset AD. In the central nervous system, TREM2 is expressed primarily in ...
Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that ...
WATERTOWN, Mass. - Vigil Neuroscience , Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company, has announced the progression of its Alzheimer’s disease (AD) candidate, VG-3927, into a Phase 2 ...
Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report) and keeping the price ...
Research from VIB-UGent identifies lipid-associated macrophages and LAM-like Kupffer cells as critical for liver repair. The ...
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of amyotrophic lateral ...
Hosted on MSN1mon
Vigil Neuroscience initiated with an Outperform at William BlairVigil is developing a unique TREM2-targeting therapeutics pipeline to treat both rare and highly prevalent degenerative disorders, the analyst tells investors in a research note. The firm says ...
Among the companies to provide updates at the J.P. Morgan Healthcare Conference in San Francisco was Vigil Neuroscience Inc., which has intrigued Wall Street more since the deal signed in December by ...
Vigil Neuroscience Inc. (NASDAQ:VIGL) released data from its completed Phase 1 trial evaluating VG-3927 as a potential treatment for Alzheimer’s disease. Key takeaways from the Phase 1 clinical trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback